Inventor · disambiguated record
Julian A. Codelli
Also filed as: CODELLI JULIAN A · Codelli Julian Andrew
21 granted patents·9 pending applications·42 citations·filing 2016–2025
92Inventor score
Files withGILEAD SCIENCES INC30
Top patents by PatentIndex Score
30 records- 0194US11224600B2Compounds for inhibition of alpha 4 beta 7 integrinGILEAD SCIENCES INC·Filed 2019·Granted Jan 18, 2022·9 cites·21 claims
- 0293US11897878B2Substituted 6-azabenzimidazole compoundsGILEAD SCIENCES INC·Filed 2021·Granted Feb 13, 2024·2 cites·65 claims
- 0392US11925631B2Substituted 6-azabenzimidazole compoundsGILEAD SCIENCES INC·Filed 2021·Granted Mar 12, 2024·2 cites·37 claims
- 0492US11897862B2IKAROS zinc finger family degraders and uses thereofGILEAD SCIENCES INC·Filed 2023·Granted Feb 13, 2024·2 cites·10 claims
- 0589US11845723B2Diacylglycerol kinase modulating compoundsGILEAD SCIENCES INC·Filed 2020·Granted Dec 19, 2023·3 cites·41 claims
- 0689US11453681B2Substituted eneoxindoles and uses thereofGILEAD SCIENCES INC·Filed 2020·Granted Sep 27, 2022·2 cites·53 claims
- 0789US11179383B2Compounds for inhibition of α4β7 integrinGILEAD SCIENCES INC·Filed 2019·Granted Nov 23, 2021·3 cites·20 claims
- 0889US11071730B2Substituted 6-azabenzimidazole compoundsGILEAD SCIENCES INC·Filed 2019·Granted Jul 27, 2021·4 cites·40 claims
- 0988US11976072B2Diacylglycerol kinase modulating compoundsGILEAD SCIENCES INC·Filed 2022·Granted May 7, 2024·1 cites·19 claims
- 1088US11203591B2Substituted 6-azabenzimidazole compoundsGILEAD SCIENCES INC·Filed 2019·Granted Dec 21, 2021·6 cites·45 claims
- 1183US11174256B2Imidazopyridine derivativesGILEAD SCIENCES INC·Filed 2019·Granted Nov 16, 2021·2 cites·18 claims
- 1283US11116760B2Quinoline derivativesGILEAD SCIENCES INC·Filed 2019·Granted Sep 14, 2021·3 cites·23 claims
- 1380US2025361236A9Diacylglycerol kinase modulating compoundsGILEAD SCIENCES INC·Filed 2024·Application pending·0 cites
- 1479US9951065B2Benzimidazole and imadazopyridine carboximidamide compoundsGILEAD SCIENCES INC·Filed 2016·Granted Apr 24, 2018·3 cites·23 claims
- 1579US2025382278A1Ikaros zinc finger family degraders and uses thereofGILEAD SCIENCES INC·Filed 2025·Application pending·0 cites
- 1678US12258346B2Substituted 6-azabenzimidazole compoundsGILEAD SCIENCES INC·Filed 2023·Granted Mar 25, 2025·0 cites·23 claims
- 1777US2025032473A1Quinoline derivativesGILEAD SCIENCES INC·Filed 2024·Application pending·0 cites
- 1875US12358887B2IKAROS Zinc Finger Family degraders and uses thereofGILEAD SCIENCES INC·Filed 2023·Granted Jul 15, 2025·0 cites·7 claims
- 1970US12037342B2Substituted eneoxindoles and uses thereofGILEAD SCIENCES INC·Filed 2022·Granted Jul 16, 2024·0 cites·54 claims
- 2068US12053462B2Quinoline derivativesGILEAD SCIENCES INC·Filed 2021·Granted Aug 6, 2024·0 cites·18 claims
- 2165US2022226337A1Compounds for inhibition of alpha 4 beta 7 integrinGILEAD SCIENCES INC·Filed 2021·Application pending·0 cites
- 2265US2022152014A1Compounds for inhibition of alpha 4 beta 7 integrinGILEAD SCIENCES INC·Filed 2021·Application pending·0 cites
- 2363US2022135561A1Imidazopyridine derivativesGILEAD SCIENCES INC·Filed 2021·Application pending·0 cites
- 2461US2024124412A1Ikaros zinc finger family degraders and uses thereofGILEAD SCIENCES INC·Filed 2022·Application pending·0 cites
- 2560US11999733B2Diacylglycerol kinase modulating compoundsGILEAD SCIENCES INC·Filed 2022·Granted Jun 4, 2024·0 cites·19 claims
- 2659US11926628B2Diacylglyercol kinase modulating compoundsGILEAD SCIENCES INC·Filed 2022·Granted Mar 12, 2024·0 cites·20 claims
- 2758US2024217990A1Thienopyrrole compoundsGILEAD SCIENCES INC·Filed 2022·Application pending·0 cites
- 2848US2025353817A1Interlukin-17a inhibitors and uses thereofGILEAD SCIENCES INC·Filed 2025·Application pending·0 cites
- 2945US10479770B2Phosphatidylinositol 3-kinase inhibitorsGILEAD SCIENCES INC·Filed 2017·Granted Nov 19, 2019·0 cites·13 claims
- 3041US10214519B2Phosphatidylinositol 3-kinase inhibitorsGILEAD SCIENCES INC·Filed 2017·Granted Feb 26, 2019·0 cites·20 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →